Skip to main content

Table 4 225Ac (including daughters) and 227Ac (including daughters) absorbed doses for selected tissues1

From: Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis

  Absorbed dose (mGy/1 MBq 225/7Ac administered); RBE not applied
225Ac + daughters 227Ac + daughters
Alpha Beta Electron Photon Total Alpha Beta Electron Photon Total
Red marrow 5.40E+02 1.32E+00 1.23E+00 1.28E−01 5.43E+02 6.66E−03 1.09E−04 1.05E−04 1.62E−05 6.89E−03
Spleen 3.74E+02 8.37E−01 6.64E−01 1.62E−01 3.76E+02 6.23E−03 2.06E−05 8.56E−05 2.17E−05 6.36E−03
Endosteal bone surface 2.48E+02 5.75E−01 4.19E−01 5.53E−02 2.49E+02 1.81E−02 1.26E−04 9.30E−05 4.95E−05 1.84E−02
Liver 5.59E+01 4.13E−01 1.02E−01 7.61E−02 5.65E+01 6.82E−04 4.05E−06 9.34E−06 6.98E−06 7.03E−04
Lungs 4.48E+00 7.14E−02 9.08E−03 5.22E−02 4.61E+00 1.42E−04 4.22E−06 1.16E−06 5.52E−06 1.53E−04
Kidneys 1.49E+00 2.61E−03 2.71E−03 5.42E−02 1.54E+00 5.86E−04 1.38E−06 7.21E−06 7.44E−06 6.02E−04
Pancreas 1.34E+00 1.84E−02 2.53E−03 5.12E−02 1.41E+00 4.25E−05 9.62E−07 3.31E−07 5.56E−06 4.94E−05
Adrenals 1.25E+00 2.83E−02 2.77E−03 9.02E−02 1.37E+00 3.98E−05 1.64E−06 3.59E−07 9.31E−06 5.11E−05
Heart wall 1.11E+00 1.89E−02 2.27E−03 4.90E−02 1.18E+00 3.52E−05 9.72E−07 2.86E−07 4.83E−06 4.13E−05
Thyroid 9.95E−01 1.25E−02 1.84E−03 3.60E−02 1.05E+00 3.16E−05 7.87E−07 2.46E−07 4.45E−06 3.71E−05
Ovaries 5.46E−01 7.01E−03 1.02E−03 3.75E−02 5.91E−01 2.38E−04 7.09E−07 2.95E−06 6.00E−06 2.47E−04
Thymus 3.61E−01 1.61E−02 1.29E−03 5.32E−02 4.32E−01 1.15E−05 1.87E−06 1.59E−07 5.70E−06 1.92E−05
Uterus 3.61E−01 4.94E−03 6.80E−04 3.47E−02 4.02E−01 1.15E−05 5.15E−07 1.03E−07 6.12E−06 1.82E−05
Breast 3.61E−01 4.77E−03 6.74E−04 2.02E−02 3.87E−01 1.15E−05 3.11E−07 8.85E−08 2.06E−06 1.39E−05
Brain 2.87E−01 6.25E−03 6.61E−04 1.76E−02 3.12E−01 9.12E−06 2.78E−06 1.40E−07 4.70E−06 1.67E−05
Muscle 1.89E−01 6.02E−03 5.51E−04 2.05E−02 2.16E−01 6.00E−06 1.63E−06 9.57E−08 3.26E−06 1.10E−05
Salivary glands 0.00E+00 1.03E−03 4.50E−05 2.22E−02 2.32E−02 0.00E+00 1.99E−06 5.18E−08 4.49E−06 6.54E−06
Eye lens 0.00E+00 2.49E−05 1.65E−07 1.10E−02 1.10E−02 0.00E+00 6.06E−08 5.69E−10 2.95E−06 3.01E−06
  1. 1Assuming 0.7% 227Ac in accelerator produced 225/7Ac and that 70% of the 227Th produced by beta decay of 227Ac-labeled antibody
  2. remains attached to the antibody